Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Gut Parabacteroides merdae protects against cardiovascular damage by enhancing branched-chain amino acid catabolism

Nature Metabolism volume 4, pages 1271–1286 (2022)Cite this article

Subjects

A Publisher Correction to this article was published on 18 January 2023

This article has been updated

Abstract

Obesity, dyslipidemia and gut dysbiosis are all linked to cardiovascular diseases. A Ganoderma meroterpene derivative (GMD) has been shown to alleviate obesity and hyperlipidemia through modulating the gut microbiota in obese mice. Here we show that GMD protects against obesity-associated atherosclerosis by increasing the abundance of Parabacteroides merdae in the gut and enhancing branched-chain amino acid (BCAA) catabolism. Administration of live P. merdae to high-fat-diet-fed ApoE-null male mice reduces atherosclerotic lesions and enhances intestinal BCAA degradation. The degradation of BCAAs is mediated by the porA gene expressed in P. merdae. Deletion of porA from P. merdae blunts its capacity to degrade BCAAs and leads to inefficacy in fighting against atherosclerosis. We further show that P. merdae inhibits the mTORC1 pathway in atherosclerotic plaques. In support of our preclinical findings, an in silico analysis of human gut metagenomic studies indicates that P. merdae and porA genes are depleted in the gut microbiomes of individuals with atherosclerosis. Our results provide mechanistic insights into the therapeutic potential of GMD through P. merdae in treating obesity-associated cardiovascular diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: HFD-fed ApoE−/− mice treated with GMD exhibit reduced atherosclerosis.
Fig. 2: GMD-mediated changes of gut microbiota in HFD-fed ApoE−/− mice.
Fig. 3: Gavage with live P. merdae attenuates the formation of atherosclerotic plaque.
Fig. 4: Identification of branched-chain amino acid degradation pathways in P. merdae.
Fig. 5: Increased BCAA degradation by P. merdae attenuates the formation of atherosclerotic plaque in HFD-fed −/− mice.
Fig. 6: Gut BCAA degradation by P. merdae regulates plaque macrophage mTORC1 signaling.

Similar content being viewed by others

Data availability

Raw sequence data from all 16S rRNA sequencing experiments are deposited in the National Center for Biotechnology Information GenBank repository (BioProject nos PRJNA870664 and PRJNA870654). For the European cohort, which is about cardiometabolic disease, the raw shotgun-sequencing data have been deposited in the European Nucleotide Archive with accession codes PRJEB37249, PRJEB38742, PRJEB41311 and PRJEB46098 and the serum metabolome data have been uploaded to MassIVE with accession MSV000088042 and MSV000088043. For the Chinese population cohort, which is about atherosclerosis, the metagenomic shotgun-sequencing data have been deposited in the European Bioinformatics Institute database under the accession code ERP023788. Additional information and materials will be made available upon reasonable request. Source data are provided with this paper.

Code availability

Any code used to analysis or plot data in this manuscript is available from the corresponding author upon request.

Change history

References

  1. Jagannathan, R., Patel, S. A., Ali, M. K. & Narayan, K. M. V. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors. Curr. Diabetes Rep. 19, 44 (2019).

    Article  Google Scholar 

  2. Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317–325 (2011).

    Article  CAS  Google Scholar 

  3. Libby, P. The changing landscape of atherosclerosis. Nature 592, 524–533 (2021).

    Article  CAS  Google Scholar 

  4. Roy, P., Orecchioni, M. & Ley, K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat. Rev. Immunol. 22, 251–265 (2021).

    Article  Google Scholar 

  5. Bergheanu, S. C., Bodde, M. C. & Jukema, J. W. Pathophysiology and treatment of atherosclerosis: current view and future perspective on lipoprotein modification treatment. Neth. Heart J. 25, 231–242 (2017).

    Article  CAS  Google Scholar 

  6. Aherrahrou, R. et al. Genetic regulation of atherosclerosis-relevant phenotypes in human vascular smooth muscle cells. Circ. Res. 127, 1552–1565 (2020).

    Article  CAS  Google Scholar 

  7. Goonewardena, S. N., Prevette, L. E. & Desai, A. A. Metabolomics and atherosclerosis. Curr. Atheroscler. Rep. 12, 267–272 (2010).

    Article  CAS  Google Scholar 

  8. Li, D. Y. & Tang, W. H. W. Gut microbiota and atherosclerosis. Curr. Atheroscler. Rep. 19, 39 (2017).

    Article  Google Scholar 

  9. Pan, H. Z. et al. Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. Circulation 142, 2060–2075 (2020).

    Article  CAS  Google Scholar 

  10. Jonsson, A. L. & Backhed, F. Role of gut microbiota in atherosclerosis. Nat. Rev. Cardiol. 14, 79–87 (2017).

    Article  CAS  Google Scholar 

  11. Wang, Z. & Zhao, Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell 9, 416–431 (2018).

    Article  CAS  Google Scholar 

  12. Bennett, B. J. et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 17, 49–60 (2013).

    Article  CAS  Google Scholar 

  13. Martin-Gallausiaux, C., Marinelli, L., Blottiere, H. M., Larraufie, P. & Lapaque, N. SCFA: mechanisms and functional importance in the gut. Proc. Nutr. Soc. 80, 37–49 (2021).

    Article  CAS  Google Scholar 

  14. Wang, Y. F., Ding, W. X. & Li, T. G. Cholesterol and bile acid-mediated regulation of autophagy in fatty liver diseases and atherosclerosis. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1863, 726–733 (2018).

    Article  CAS  Google Scholar 

  15. Wang, K. et al. Structural modification of natural product ganomycin I leading to discovery of a α-glucosidase and HMG-CoA reductase dual inhibitor improving obesity and metabolic dysfunction in vivo. J. Med. Chem. 61, 3609–3625 (2018).

    Article  CAS  Google Scholar 

  16. Qiao, S. S. et al. Activation of a specific gut Bacteroides–folate–liver axis benefits for the alleviation of nonalcoholic hepatic steatosis. Cell Rep. 32, 108005 (2020).

    Article  CAS  Google Scholar 

  17. Qiao, S. S. et al. The enriched gut commensal Faeciroseburia intestinalis contributes to the anti-metabolic disorders effects of the Ganoderma meroterpene derivative. Food Sci. Hum. Wellness 11, 85–96 (2022).

    Article  CAS  Google Scholar 

  18. Wang, K. et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep. 26, 222–235 (2019).

    Article  Google Scholar 

  19. Beckman, J. A., Creager, M. A. & Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J. Am. Med. Assoc. 287, 2570–2581 (2002).

    Article  CAS  Google Scholar 

  20. Stols-Gonçalves, D., Hovingh, G. K., Nieuwdorp, M. & Holleboom, A. G. NAFLD and atherosclerosis: two sides of the same dysmetabolic coin? Trends Endocrinol. Metab. 30, 891–902 (2019).

    Article  Google Scholar 

  21. Wouters, K., Shiri-Sverdlov, R., van Gorp, P. J., van Bilsen, M. & Hofker, M. H. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin. Chem. Lab. Med. 43, 470–479 (2005).

    Article  CAS  Google Scholar 

  22. King, V. L. et al. A murine model of obesity with accelerated atherosclerosis. Obesity 18, 35–41 (2010).

    Article  CAS  Google Scholar 

  23. Li, T. et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury. Cell Metab. 25, 374–385 (2017).

    Article  CAS  Google Scholar 

  24. Sun, H. P. et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133, 2038–2049 (2016).

    Article  CAS  Google Scholar 

  25. Xu, Y., Jiang, H., Li, L., Chen, F. & Liu, J. J. C. Branched-chain amino acid catabolism promotes thrombosis risk by enhancing tropomodulin-3 propionylation in platelets. Circulation 142, 49–64 (2020).

    Article  CAS  Google Scholar 

  26. Kampoli, A. M., Tousoulis, D., Antoniades, C., Siasos, G. & Stefanadis, C. Biomarkers of premature atherosclerosis. Trends Mol. Med. 15, 323–332 (2009).

    Article  CAS  Google Scholar 

  27. Gorabi, A. M. et al. Implications for the role of lipopolysaccharide in the development of atherosclerosis. Trends Cardiovasc. Med. 21, S1050–S1738 (2021).

    Google Scholar 

  28. Soeki, T. & Sata, M. Inflammatory biomarkers and atherosclerosis. Int. Heart J. 57, 134–139 (2016).

    Article  CAS  Google Scholar 

  29. Santilli, A. D., Dawson, E. M., Whitehead, K. J. & Whitehead, D. C. Nonmicrobicidal small molecule inhibition of polysaccharide metabolism in human gut microbes: a potential therapeutic avenue. ACS Chem. Biol. 13, 1165–1172 (2018).

    Article  CAS  Google Scholar 

  30. Douglas, G. M. et al. PICRUSt2 for prediction of metagenome functions. Nat. Biotechnol. 38, 685–688 (2020).

    Article  CAS  Google Scholar 

  31. Jie, Z. et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat. Commun. 8, 845 (2017).

    Article  Google Scholar 

  32. Fromentin, S. et al. Microbiome and metabolome features of the cardiometabolic disease spectrum. Nat. Med. 28, 303–314 (2022).

    Article  CAS  Google Scholar 

  33. Lee, C. C. et al. Branched-chain amino acids and insulin metabolism: the insulin resistance atherosclerosis study (IRAS). Diabetes Care 39, 582–588 (2016).

    Article  CAS  Google Scholar 

  34. Tobias, D. K. et al. Circulating branched-chain amino acids and incident cardiovascular disease in a prospective cohort of US women. Circ. Genom. Precis. Med. 11, e002157 (2018).

    Article  CAS  Google Scholar 

  35. Bo, H. et al. A diabetes-predictive amino acid score and future cardiovascular disease. Eur. Heart J. 34, 1982–1989 (2013).

    Article  Google Scholar 

  36. Bhattacharya, S. et al. Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis 232, 191–196 (2014).

    Article  CAS  Google Scholar 

  37. Ridaura, V. K. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1079–U1049 (2013).

    Article  CAS  Google Scholar 

  38. Guo, C. J. et al. Depletion of microbiome-derived molecules in the host using Clostridium genetics. Science 366, e1331 (2019).

    Article  Google Scholar 

  39. Andreu, V. P., Roel-Touris, J., Dodd, D., Fischbach, M. A. & Medema, M. H. The gutSMASH web server: automated identification of primary metabolic gene clusters from the gut microbiota. Nucleic Acids Res. 49, W263–W270 (2021).

    Article  CAS  Google Scholar 

  40. Newgard, C. B. et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9, 311–326 (2009).

    Article  CAS  Google Scholar 

  41. Fontana, L. et al. Decreased consumption of branched chain amino acids improves metabolic health. Cell Rep. 16, 520–530 (2016).

    Article  CAS  Google Scholar 

  42. Yu, D. Y. et al. The adverse metabolic effects of branched-chain amino acids are mediated by isoleucine and valine. Cell Metab. 33, 905–922 (2021).

    Article  CAS  Google Scholar 

  43. Guillén, C. & Benito, M. mTORC1 overactivation as a key aging factor in the progression to type 2 diabetes mellitus. Front. Endocrinol. 9, 621 (2018).

    Article  Google Scholar 

  44. Cheon, S. Y. & Cho, K. Lipid metabolism, inflammation, and foam cell formation in health and metabolic disorders: targeting mTORC1. J. Mol. Med. 99, 1497–1509 (2021).

    Article  CAS  Google Scholar 

  45. Christopher, G. P. Regulation of mammalian translation factors by nutrients. Eur. J. Biochem. 269, 5338–5349 (2002).

    Article  Google Scholar 

  46. Zhang, X. et al. High-protein diets increase cardiovascular risk by activating macrophage mTOR to suppress mitophagy. Nat. Metab. 2, 110–125 (2020).

    Article  CAS  Google Scholar 

  47. Zhenyukh, O. et al. Branched-chain amino acids promote endothelial dysfunction through increased reactive oxygen species generation and inflammation. J. Cell. Mol. Med. 22, 4948–4962 (2018).

    Article  CAS  Google Scholar 

  48. Zhou, M. Z. et al. Targeting BCAA catabolism to treat obesity-associated insulin resistance. Diabetes 68, 1730–1746 (2019).

    Article  CAS  Google Scholar 

  49. Fingar, D. C. & Blenis, J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151–3171 (2004).

    Article  CAS  Google Scholar 

  50. Liang, H., Jiang, F., Cheng, R., Luo, Y. & He, F. A high-fat diet and high-fat and high-cholesterol diet may affect glucose and lipid metabolism differentially through gut microbiota in mice. Exp. Anim. 70, 73–83 (2021).

    Article  CAS  Google Scholar 

  51. Neinast, M. D. et al. Quantitative analysis of the whole-body metabolic fate of branched-chain amino acids. Cell Metab. 29, 417–429 (2019).

    Article  CAS  Google Scholar 

  52. Wang, Z. N. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585–1595 (2015).

    Article  CAS  Google Scholar 

  53. Chen, P. B. et al. Directed remodeling of the mouse gut microbiome inhibits the development of atherosclerosis. Nat. Biotechnol. 38, 1288–1297 (2020).

    Article  CAS  Google Scholar 

  54. Wang, K. et al. A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-Ay mice. Eur. J. Med. Chem. 127, 1035–1046 (2017).

    Article  CAS  Google Scholar 

  55. Wu, T. R. et al. Gut commensal Parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis. Gut 68, 248–262 (2019).

    Article  CAS  Google Scholar 

  56. Sato, Y. et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature 599, 458–464 (2021).

    Article  CAS  Google Scholar 

  57. Olson, C. A. et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 173, 1728–1741 (2018).

    Article  CAS  Google Scholar 

  58. Li, J., Lin, S. Q., Vanhoutte, P. M., Woo, C. W. & Xu, A. M. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe−/− mice. Circulation 133, 2434–2446 (2016).

    Article  CAS  Google Scholar 

  59. Pedersen, H. K. et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376–381 (2016).

    Article  CAS  Google Scholar 

  60. Oh, S. F. et al. Host immunomodulatory lipids created by symbionts from dietary amino acids. Nature 600, 302–307 (2021).

    Article  CAS  Google Scholar 

  61. Heimann, E., Nyman, M., Palbrink, A. K., Lindkvist-Petersson, K. & Degerman, E. Branched short-chain fatty acids modulate glucose and lipid metabolism in primary adipocytes. Adipocyte 5, 359–368 (2016).

    Article  CAS  Google Scholar 

  62. Bellono, N. W. et al. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell 170, 185–198 (2017).

    Article  CAS  Google Scholar 

  63. Liu, C. et al. Enlightening the taxonomy darkness of human gut microbiomes with a cultured biobank. Microbiome 9, 119 (2021).

    Article  CAS  Google Scholar 

  64. Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME. Nat. Biotechnol. 37, 852–857 (2019).

    Article  CAS  Google Scholar 

  65. Zgadzaj, R. et al. Root nodule symbiosis in Lotus japonicus drives the establishment of distinctive rhizosphere, root, and nodule bacterial communities. Proc. Natl Acad. Sci. USA 113, E7996–E8005 (2016).

    Article  CAS  Google Scholar 

  66. Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).

    Article  Google Scholar 

Download references

Acknowledgements

This work was financially supported by the National Key R&D program of China (2019YFA0905602), the Chinese Academy of Sciences Strategic Priority Research Program (class B) (XDB38020300) and the National Natural Science Foundation of China (81773614).

Author information

Author notes

  1. These authors contributed equally: Shanshan Qiao, Chang Liu.

Authors and Affiliations

  1. State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, PR China

    Shanshan Qiao, Li Sun, Tao Wang, Huanqin Dai, Kai Wang, Li Bao, Hantian Li, Wenzhao Wang & Hongwei Liu

  2. Savaid Medical School, University of Chinese Academy of Sciences, Beijing, PR China

    Shanshan Qiao, Li Sun, Tao Wang, Huanqin Dai, Kai Wang, Li Bao, Hantian Li, Shuang-Jiang Liu & Hongwei Liu

  3. State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, PR China

    Chang Liu & Shuang-Jiang Liu

Authors
  1. Shanshan Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huanqin Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hantian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wenzhao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shuang-Jiang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hongwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S.S.Q. and H.W.L. were responsible for study conceptualization. S.S.Q., L.S., T.W., H.Q.D., W.Z.W. and H.W.L. were responsible for the methodology. Formal analysis was conducted by S.S.Q., C.L. and K.W. Investigation was carried out by S.S.Q., K.W. and L.B. S.S.Q. and C.L. were responsible for resources. S.S.Q. and H.W.L. wrote the original draft. S.S.Q., H.T.L. and H.W.L. were responsible for writing review & editing. Supervision was carried out by S.J.L. and H.W.L. Funding acquisition was the responsibility of H.W.L.

Corresponding authors

Correspondence to Shuang-Jiang Liu or Hongwei Liu.

Ethics declarations

Competing interests

H.W.L. has a patent related to this work (CN202110786071.9). All other authors declare no competing interests.

Peer review

Peer review information

Nature Metabolism thanks Esther Lutgens, Herbert Tilg and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Ashley Castellanos-Jankiewicz, in collaboration with the Nature Metabolism team.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Effects of GMD on food intake, body weight gain, body composition, and hepatic steatosis in the HFD-fed ApoE−/− mice.

a, Cumulative food intake (**P = 0.0021). b, Body weight gain (Mod vs. Con: ***P = 0.0008, ****P = 0.0001, **** P < 0.0001, **** P < 0.0001, **** P < 0.0001 and **** P < 0.0001; Mod vs. Statin: *P = 0.0271, ***P = 0.0003 and **P = 0.0062; Mod vs. GMDL: **P = 0.0014, **P = 0.0041, ***P = 0.0003, **** P < 0.0001, **P = 0.0016, ****P = 0.0001, ****P < 0.0001, ****P < 0.0001 and ****P = 0.0001; Mod vs. GMDH: **P = 0.0023, *P = 0.0170, **P = 0.0097, **P = 0.0037, **P = 0.0044, **P = 0.0010, ***P = 0.0004, ****P < 0.0001 and ****P = 0.0001). c, Lean. d, Fat (**** P < 0.0001, **** P < 0.0001 and **** P < 0.0001). e, Inguinal fat (**** P < 0.0001, **** P < 0.0001 and **** P < 0.0001). f, Mesenteric fat (*P = 0.0271). g, Representative images of liver sections after HE or oil red O staining. Abbreviation: Con, normal diet-fed C57BL/6 J mice; Mod, HFD-fed ApoE−/− mice treated with vehicle; Statin, HFD-fed ApoE−/− mice treated with 10 mg/kg atorvastatin; GMDL, HFD-fed ApoE−/− mice treated with 5 mg/kg GMD; GMDH, HFD-fed ApoE−/− mice treated with 10 mg/kg GMD. n = 8 for each group. Data is presented as the mean ±s.e.m. Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. The P values in each panel were given from left to right, respectively.

Source data

Extended Data Fig. 2 GMD alters the gut microbiota in the HFD-fed ApoE−/− mice.

a, Species accumulation curve. b, α-diversity of the gut microbiota between ApoE−/− +HFD and ApoE−/− +HFD + GMDH groups, as indicated by the observed species, Shannon and Chao1indices. c, Sankey diagram showing the genus of contribution differently among two groups. d, A heat map of the most abundant top 35 bacteria at the genus level among two groups. Blue denotes a low relative abundance across a taxon (row); red denotes a high relative abundance. The color key for the Z score indicates correspondence between the red-blue coloring and standard deviations from the mean abundance of each taxon. Abbreviation: ApoE−/− +HFD, HFD-fed ApoE−/− mice treated with vehicle; ApoE−/− +HFD + GMDH, HFD-fed ApoE−/− mice treated with 10 mg/kg GMD.

Source data

Extended Data Fig. 3 Relative abundances of P. merdae, porA gene reads, and the level of serum BCAAs across a Chinese gut metagenome or European gut metagenome and metabolome.

a-c, The relative abundance of P. merdae (a, *P = 0.0255) and porA gene (b, ****P < 0.0001) in each gut metagenomic dataset, and the positive correlation (c, R2 = 0.261 and P < 0.0001) between the gut metagenomes of atherosclerosis cohorts (n = 214) and their healthy counterparts (n = 171). d and e, The relative abundance of P. merdae (d, **P = 0.0028, **P = 0.0012 and ****P < 0.0001) and the serum BCAAs levels (e, *** P < 0.0001 for listed all comparisons; The exact concentrations of serum BCAAs in each sample were also shown in Supplementary Table 12 from Nature Medicine, VOL 28, P303–P314, 2022, www.nature.com/naturemedicine) in a European cohort study. The study recruited 647 fecal donors comprising a combined group of patients diagnosed with ischemic heart disease (IHD, n = 372 with different drugs) which included cases with acute coronary syndrome (ACS, n = 112), chronic ischemic heart disease (CIHD, n = 158) and heart failure (HF, n = 102) due to CIHD, and the healthy control (HC, n = 275, health by self-report and no intake of lipid-lowering, anti-diabetic or anti-hypertensive drugs). For panel c, R value refers to the standardized effect size estimated by the linear regression, and the corresponding P value is shown. For the other panels, the P values were obtained from Two-tailed Student’s t-tests, * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. The P values in each panel were given from left to right, respectively.

Source data

Extended Data Fig. 4 Parabacteroides merdae alters the gut microbiota and reduce hepatic steatosis in the HFD-fed ApoE−/− mice.

a, α-diversity of the gut microbiota between ApoE−/− and PM groups, as indicated by the observed species, Chao1, Shannon, Pielou_e, and Simpson indices. b, Principal coordinate analysis (PCoA) of all samples at the genus level among two groups. c, PCoA of all samples at the species level among two groups. d, A heat map of the most abundant top 30 bacteria at the genus level among two groups and the importance of species to the model decreased from top to bottom, which could be considered as indicators of inter-group differences. e, A heat map of the most abundant top 30 bacteria at the species level among two groups. Blue denotes a low relative abundance across a taxon (row); red denotes a high relative abundance. The color key for the Z score indicates correspondence between the red-blue coloring and standard deviations from the mean abundance of each taxon. f. Representative images of liver sections after HE or oil red O staining. Abbreviation: ApoE−/−, HFD-fed ApoE−/− mice treated with vehicle; PM, HFD-fed ApoE−/− mice treated with P. merdae (2 × 108 CFU/day). n = 10 for each group.

Source data

Extended Data Fig. 5 Gavage with the live P. merdae attenuates hyperlipidemia, hyperglycemia, and atherosclerosis biomarkers in Abx pre-treatment ApoE−/− mice.

a, Experimental design showing groups and durations. b, Body weight change (**P = 0.0025, **P = 0.0031, **P = 0.0047, **P = 0.0018, *P = 0.0109, *P = 0.0446, *P = 0.0155, **P = 0.0018, **P = 0.0018 and *P = 0.0242). c, White fat (P = 0.0073). d, Levels of plasma T-C (*P = 0.0142), T-TG (**P = 0.0086), LDL-C, and HDL-C. e, Plasma ox-LDL (*P = 0.0309). f, Plasma LPS (***P = 0.0004). g, Plasma MCP-1 (**P = 0.0013). h, Plasma TNF-α (*P = 0.0213). i, Plasma IL-1β (**P = 0.0088). j, Plasma hs-CRP. k, Plasma HbA1c (**P = 0.0058). l, Plasma sINS. m, OGTT test (*P = 0.0300). n, AUC of OGTT (*P = 0.0790). o, AOC of OGTT (*P = 0.0228). p, ITT test (*P = 0.0146, *P = 0.0127 and *P = 0.0194). q, AUC of ITT (**P = 0.004). r, AOC of ITT. n = 8 for each group. Abbreviation: ApoE, Abx pre-treatment ApoE−/− mice treated with vehicle; P. merdae, Abx pre-treatment ApoE−/− mice treated with treated with P. merdae (2 × 108 CFU/day). Data is presented as mean ± s.e.m. Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. AVNM: antibiotics (ampicillin, vancomycin, neomycin, metronidazole). The P values in each panel were given from left to right, respectively.

Source data

Extended Data Fig. 6 Analysis of BCAAs catabolism in the P. merdae and construction of porA-deficient strain of P. merdae.

a, PorA gene cluster for BCAAs metabolism predicted by gutSMASH in P. merdae genome. b, PorA gene cluster in P. merdae genome and its homologs-MGC00000015_c1 in Clostridium sporogenes. c, Schematic layout of mutant construction. d, Validation of pGERM::porA insertion into porA gene of P. merdae genome. e, Growth of strain PMΔporA and PMWT on Gifu anaerobic medium, mid log phases are pointed by gray arrows and late log phases by black arrows. n = 3 for each group.

Source data

Extended Data Fig. 7 The transcription levels of BCAA catabolic enzymes, the level of blood glucose, and insulin sensitivity in the high-fat diet-fed ApoE−/− mice treated with the wild-type or mutant strain of P. merdae.

Real-time RT-PCR result of indicated genes using mRNA from (a) liver (b) muscle (c) adipose of PMΔporA and PMWT; n = 6 for each group. d, Plasma 3-HIB (3-hydroxyisobutyrate) levels, n = 8 for each group. e, Free diet blood glucose (C57 vs. ApoE−/−: **P = 0.0031, ****P < 0.0001, **P = 0.0044, **P = 0.0016 and ***P = 0.0003; PMWT vs. ApoE−/−: *P = 0.0334 and *P = 0.0246); n = 10 for C57 and n = 12 for the other three groups. f, ITT Test (C57 vs. ApoE−/−: ***P = 0.0005, ***P = 0.0002, ****P < 0.0001 and ****P < 0.0001; PMWT vs. ApoE−/−: ***P = 0.0003, ****P < 0.0001 ****P = 0.0001 and ****P = 0.0001; PMΔPorA vs. ApoE−/−: *P = 0.0232); n = 8 for C57 and n = 10 for the other three groups. g, AOC of ITT; n = 8 for C57 and n = 10 for the other three groups. h, AUC of ITT (****P < 0.0001 for all three comparisons); n = 9 for ApoE−/− and n = 10 for the other three groups. Abbreviation: C57: normal-diet-fed C57BL/6 J mice; ApoE−/−, HFD-fed ApoE−/− mice; PMΔPorA, HFD-fed ApoE−/− mice treated with porA-deficient P. merdae mutant; PMWT, HFD-fed ApoE−/− mice treated with wild-type P. merdae. Data is mean ± s.e.m. Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. The P values in each panel were given from left to right, respectively.

Source data

Extended Data Fig. 8 IgA levels in atherosclerotic plaques and plasma of ApoE−/− mice treated with the wild-type or mutant strain of P. merdae.

a, Immunostaining of IgA (red) levels and the macrophage marker CD68 (green) in atherosclerotic plaques; Representative images are shown on the left and quantification on the above; n = 5 for each group; AU, arbitrary units; Scale bars, 100 μm (left), 50 μm (right). b, Plasma secreted IgA (*P = 0.0359); n = 12 for each group. Abbreviation: PMΔPorA, ApoE−/− mice treated with porA-deficient P. merdae mutant; PMWT, ApoE−/− mice treated with wild-type P. merdae. Data is presented as mean ± s.e.m. Statistical analysis was performed using Unpaired two-sided Student’s t-test (Gaussian model). * P < 0.05.

Source data

Extended Data Fig. 9 Efficacy comparison of GMD and P. merdae on high cholesterol diet (HCD) -fed ApoE−/− mice or high-fat diet (HFD) -fed ApoE−/− mice.

a, Experimental design showing groups and durations. b, Body weight (HFD vs. HFD + GMD: *P = 0.0432, *P = 0.0207, **P = 0.0028, *P = 0.0150, **P = 0.0030 and **P = 0.0011); n = 6 for each group. c, Plasma cholesterol parameters CHO (*P = 0.0216 and ****P = 0.0001); LDL-C (*P = 0.0129 and ****P = 0.0001) and HDL-C (****P = 0.0001); n = 5 for HCD and HCD + GMD, n = 6 for HFD and HFD + GMD. d, Plasma TG (**P = 0.0010); n = 5 for HCD and n = 6 for the other three groups. e, Free diet glucose (**P = 0.0015). f, Plasma hs-CRP (**P = 0.0011); n = 6 for HFD + GMD and n = 5 for the other three groups. g, Plasma ox-LDL (**P = 0.0049); n = 5 for HCD and HCD + GMD, n = 6 for HFD and HFD + GMD. h, Representative H&E and Masson of cross-sections of blue-blackaortic roots and the quantitation of plaque area (*P = 0.0352, ***P = 0.0006 and ****P < 0.0001); n = 6 for HFD + GMD and n = 5 for the other three groups; Masson staining of a cross-section of one of the aortic roots shown in (h), cardiomyocytes (red), nucleus (blue-black), collagen (blue); scale bar = 400 μm. i, Experimental design. j, Plasma TG; n = 6 for PMWT and n = 5 for the other two groups. k, Plasma cholesterol parameters; n = 6 for PMWT and n = 5 for the other two groups. l, Plasma ox-LDL; n = 5 for HCD and n = 6 for the other two groups. m, Plasma hs-CRP; n = 6 for PMWT and n = 5 for the other two groups. n, Representative H&E and Masson of cross-sections of aortic roots and the quantitation of plaque area; n = 5 for each group; Masson staining of a cross-section of one of the aortic roots shown in (n), cardiomyocytes (red), nucleus (blue-black), collagen (blue); scale bar = 300 μm. Abbreviation: HCD, high cholesterol diet (HCD)-fed ApoE−/− mice; HCD-GMD, HCD-fed ApoE−/− mice treated with 10 mg/kg GMD; HFD, HFD-fed ApoE−/− mice; HFD-GMD, HFD-fed ApoE−/− mice treated with 10 mg/kg GMD; PMΔPorA, HCD-fed ApoE−/− mice treated with porA-deficient P. merdae mutant; PMWT, HCD-fed ApoE−/− mice treated with wild-type P. merdae. Statistical analysis was performed using one-way ANOVA followed by the Tukey post hoc test. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. The P values in each panel were given from left to right, respectively.

Source data

Extended Data Fig. 10 Influence of HCD and HFD on circulating BCAAs, insulin sensitivity, and plaque macrophage mTORC1 signaling in ApoE−/−mice.

a, Experimental design. b, Body weight (CON vs. HCD: *P = 0.0301, **P = 0.0075, **P = 0.0060, *P = 0.0157, **P = 0.0011, **P = 0.0090, ***P = 0.0008 and ***P = 0.0007; CON vs. HFD: *P = 0.0485, *P = 0.0240, **P = 0.0032, **P = 0.0014, **P = 0.0031, **P = 0.0016 and ***P = 0.0004; HCD vs. HFD: *P = 0.0225, **P = 0.0084, **P = 0.0043, ***P = 0.0002, ****P = 0.0001, ***P = 0.0005, ***P = 0.0002 and ****P = 0.0001). c, Individual body weight after 14 weeks of treatment (****P < 0.0001 and ****P < 0.0001). d, Plasma lipid parameter CHO (****P < 0.0001 and *P = 0.0155); LDL-C (****P < 0.0001 and *P = 0.0429); HDL-C (**P = 0.0038) and TG (****P < 0.0001). e, Free diet blood glucose (CON vs. HCD: *P = 0.0151, *P = 0.0380, ****P < 0.0001 and *P = 0.0261; CON vs. HFD: ***P = 0.0007, ****P < 0.0001, ****P = 0.0001, ****P = 0.0001, ***P = 0.0002 and ****P < 0.0001; HCD vs. HFD: ***P = 0.0007, ****P < 0.0001, ****P = 0.0001, ****P = 0.0001, ***P = 0.0002 and ****P < 0.0001). f, OGTT test (CON vs HCD: P = 0.0431; CON vs. HFD: ****P = 0.0001 and **P = 0.0016). g, AOC of OGTT (*P = 0.0165 and *P = 0.0265). h, AUC of OGTT (****P < 0.0001 and ****P < 0.0001). i, Plasma insulin (***P = 0.0003 and **P = 0.0019). j, Plasma ox-LDL (****P = 0.0001 and *P = 0.0104). k, Plasma hs-CRP (*P = 0.0269 and *P = 0.0115). l, Plasma BCAAs levels (*P = 0.0433, **P = 0.0016, **P = 0.0096, ***P = 0.0005, *P = 0.0112 and ***P = 0.0009). m, Fecal BCAAs levels (*P = 0.0151, **P = 0.0022 and *P = 0.0249). n, Representative H&E and Masson of cross-sections of aortic roots and quantitative data; n = 5 for each group; scale bar = 300 μm; Masson staining of a cross-section of one of the aortic roots shown in (n), cardiomyocytes (red), nucleus (blue-black), collagen (blue). o, Immunostaining of pS6 levels, colocalization of pS6 (red) with the macrophage marker CD68 (green) in atherosclerotic plaques, and the quantifications of CD68 aera, average pS6 intensity (**P = 0.0035) and CD68 with pS6 colocalization (*P = 0.0268); Representative images are shown on the top and quantification on the bottom; n = 3 for each group; AU, arbitrary units; Scale bar = 200 μm. Abbreviation: CON, Normal diet-fed C57BL/6 J mice; HCD, high cholesterol diet-fed ApoE−/− mice; HFD, high-fat diet-fed ApoE−/− mice. n = 6 for each group unless otherwise indicated. Data is presented as mean ± s.e.m. Statistical analysis was performed using unpaired two-sided Student’s t-test (Gaussian model). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. The P values in each panel were given from left to right, respectively.

Source data

Supplementary information

Source data

Source Data Fig. 1

Statistical Source Data for Fig. 1b–i.

Source Data Fig. 2

Statistical Source Data for Fig. 2a–g.

Source Data Fig. 3

Statistical Source Data for Fig. 3b–h.

Source Data Fig. 4

Statistical Source Data for Fig. 4a–d,f.

Source Data Fig. 5

Statistical Source Data for Fig. 5b–i.

Source Data Fig. 6

Statistical Source Data for Fig. 6a–i.

Source Data Extended Data Fig. 1

Statistical Source Data for Extended Data Fig. 1a–f.

Source Data Extended Data Fig. 2

Statistical Source Data for Extended Data Fig. 2a–d.

Source Data Extended Data Fig. 3

Statistical Source Data for Extended Data Fig. 3a–d.

Source Data Extended Data Fig. 4

Statistical Source Data for Extended Data Fig. 4a–e.

Source Data Extended Data Fig. 5

Statistical Source Data for Extended Data Fig. 5b–r.

Source Data Extended Data Fig. 6

Statistical Source Data for Extended Data Fig. 6e.

Source Data Extended Data Fig. 7

Statistical Source Data for Extended Data Fig. 7a–h.

Source Data Extended Data Fig. 8

Statistical Source Data for Extended Data Fig. 8a,b.

Source Data Extended Data Fig. 9

Statistical Source Data for Extended Data Fig. 9b–n.

Source Data Extended Data Fig. 10

Statistical Source Data for Extended Data Fig. 10b–o.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qiao, S., Liu, C., Sun, L. et al. Gut Parabacteroides merdae protects against cardiovascular damage by enhancing branched-chain amino acid catabolism. Nat Metab 4, 1271–1286 (2022). https://doi.org/10.1038/s42255-022-00649-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-022-00649-y

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing